31 March - 1 April 2025

8th SCI-RSC Symposium on Ion Channels as Therapeutic Targets

Organised by:

SCI’s Fine Chemicals group and RSC’s Biological & Medicinal Chemistry Sector

Cambridge, UK

Register now
Synopsis
Ion channels are important targets for therapeutic intervention due to their extensive roles in human physiology and the pathophysiology of disease. Many successful drugs targeting this gene family have been discovered for diseases such as hypertension, epilepsy, and neuropathic pain. This symposium, the 8th in an ongoing series, will showcase the most recent advances to aid the design of new ion channel therapeutics and promote interaction between scientists with a shared interest in the field of ion channel drug discovery.

Medicinal chemistry case studies of ion channels as therapeutic targets
Advances in structure determination techniques and successful structure determinations of key ion channels 
Novel pharmacology and target validation 
Emerging technologies for targeting, assaying and modulating ion channel targets.
 

Attendees

This event will be relevant to scientists from industry and academia interested in the therapeutic potential of ion channels. The organising committee particularly welcomes attendance and participation of students or early career researchers working in the field of ion channels.


Programme
To view the confirmed speakers click here.
Exhibitors and Sponsors

For further information and prices please contact events@hg3.co.uk.


Accessibility Grants

SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.


Venue and Contact

Hinxton Hall

Wellcome Genome Campus
Cambridge
CB10 1RQ

 

HG3 conferences Ltd

Tel: +44 (0)1423529333

Email: events@hg3.co.uk


Partners

Organising committee
Rose Bardell-Cox, Evotec 
Michael Clegg, MSD 
Brian Cox, University of Sussex 
Sarah Major, Dark Blue Therapeutics
Alex Preston, GSK 
Jason Tierney, MedChemica